Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity

BackgroundAnthracycline-mediated adverse cardiovascular events are among the leading causes of morbidity and mortality in patients with cancer. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) exert multiple cardiometabolic benefits in patients with/without type 2 diabetes, chronic kidney disease,...

Повний опис

Бібліографічні деталі

Автори:	V. Quagliariello, M. L. Canale, I. Bisceglia, M. Iovine, A. Paccone, C. Maurea, M. Scherillo, A. Merola, V. Giordano, G. Palma, A. Luciano, F. Bruzzese, F. Zito Marino, M. Montella, R. Franco, M. Berretta, D. Gabrielli, G. Gallucci, N. Maurea
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2024-05-01
Серія:	Frontiers in Cardiovascular Medicine
Предмети:	cancer dapagliflozin cardio-oncology cardioprotection doxorubicin NF-kB
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fcvm.2024.1289663/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!